Stanley Laman Group Ltd. Sells 1,558 Shares of Eli Lilly and Company (NYSE:LLY)

Stanley Laman Group Ltd. lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 11.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,894 shares of the company’s stock after selling 1,558 shares during the quarter. Eli Lilly and Company accounts for about 1.1% of Stanley Laman Group Ltd.’s investment portfolio, making the stock its 26th largest position. Stanley Laman Group Ltd.’s holdings in Eli Lilly and Company were worth $6,933,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Lipe & Dalton acquired a new stake in Eli Lilly and Company during the fourth quarter worth about $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $27,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company in the third quarter valued at $35,000. Optiver Holding B.V. bought a new position in Eli Lilly and Company in the third quarter worth $36,000. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company during the third quarter worth $40,000. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on LLY. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Barclays lifted their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $728.05.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 1.0 %

Shares of LLY stock traded down $7.33 on Thursday, hitting $724.87. The stock had a trading volume of 2,597,583 shares, compared to its average volume of 3,034,002. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a twelve month low of $370.68 and a twelve month high of $800.78. The company has a fifty day moving average price of $762.75 and a two-hundred day moving average price of $664.94. The firm has a market cap of $688.74 billion, a P/E ratio of 124.98, a PEG ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.09 EPS. As a group, analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.